Advertisement Halozyme, Janssen to develop and commercialize products using Enhanze technology - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Halozyme, Janssen to develop and commercialize products using Enhanze technology

US-based biopharmaceutical firm Halozyme Therapeutics has entered into a worldwide collaboration and license agreement with Janssen Biotech to develop and commercialize products combining Janssen compounds with Halozyme's Enhanze technology.

Enhanze is based on a recombinant human hyaluronidase enzyme (rHuPH20) that temporarily modifies hyaluronan, a component of the extracellular matrix, to aid in the dispersion and absorption of other injected therapeutic drugs.

As part of the deal, Halozyme has granted worldwide license to Janssen to develop and commercialize products for up to five targets combining rHuPH20 with Janssen’s proprietary compounds.

In return, Halozyme will receive an initial payment of $15m and is eligible to get additional payments of about $566m upon Janssen’s achievement of specified development, regulatory and sales-based milestones.

Based on net sales of products using the Enhanze technology, Halozyme is also entitled to royalty payments.

The deal will provide Janssen access to Halozyme’s expertise in developing and applying rHuPH20 to Janssen targets and will secure a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 and Janssen target compounds resulting from the collaboration.

The company said that by using rHuPH20, some biologics and compounds that are administered intravenously may instead be delivered subcutaneously.